Published in Thorax on July 29, 2005
Clinical And Social Characteristics and Demographics in COPD (CASCADE) | NCT02882165
Bronchial Infection in Patients With COPD and Frequent Exacerbations. | NCT03259022
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J (2007) 4.27
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax (2012) 4.06
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med (2011) 3.33
Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ (2010) 3.30
COPD exacerbations .1: Epidemiology. Thorax (2006) 2.94
The clinical features of the overlap between COPD and asthma. Respir Res (2011) 2.29
Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85
Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med (2013) 1.82
Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.77
Risk factors of hospitalization and readmission of patients with COPD exacerbation--systematic review. Int J Chron Obstruct Pulmon Dis (2007) 1.67
Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med (2013) 1.62
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res (2011) 1.52
Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort. PLoS One (2016) 1.44
Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. PLoS One (2015) 1.41
Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.38
Less smoke, more fire: What's new for you in the latest COPD guidelines? Can Fam Physician (2008) 1.38
Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis (2014) 1.32
Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res (2010) 1.26
Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med (2011) 1.25
The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J (2012) 1.23
Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis (2014) 1.23
Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? Proc Am Thorac Soc (2007) 1.22
Anemia and performance status as prognostic markers in acute hypercapnic respiratory failure due to chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2013) 1.21
Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unit. BMC Pulm Med (2006) 1.19
Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis (2009) 1.19
COPD exacerbations.5: management. Thorax (2006) 1.14
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India (2013) 1.13
The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One (2014) 1.10
Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J (2007) 1.09
Factors associated with change in exacerbation frequency in COPD. Respir Res (2013) 1.08
Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One (2012) 1.04
Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis (2011) 1.04
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis (2012) 1.03
Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med (2009) 1.02
Predictors of mortality in patients with stable COPD. J Gen Intern Med (2008) 1.01
Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulm Med (2010) 0.99
What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines. Thorax (2007) 0.98
Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J Gen Intern Med (2009) 0.98
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res (2013) 0.98
Polymorphic variation in surfactant protein B is associated with COPD exacerbations. Eur Respir J (2008) 0.98
Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J Bras Pneumol (2013) 0.97
The IRYSS-COPD appropriateness study: objectives, methodology, and description of the prospective cohort. BMC Health Serv Res (2011) 0.96
COPD: what is the unmet need? Br J Pharmacol (2008) 0.95
Using modeling to inform patient-centered care choices at the end of life. J Comp Eff Res (2013) 0.95
Sleep-disordered breathing and COPD: the overlap syndrome. Respir Care (2010) 0.94
Factors associated with frequency of emergency department visits for chronic obstructive pulmonary disease exacerbation. J Gen Intern Med (2007) 0.94
Predictive score for mortality in patients with COPD exacerbations attending hospital emergency departments. BMC Med (2014) 0.94
Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Respir Res (2015) 0.93
Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung (2013) 0.92
Evolution of the COPD Assessment Test score during chronic obstructive pulmonary disease exacerbations: determinants and prognostic value. Can Respir J (2013) 0.91
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res (2009) 0.91
Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCT. BMC Pulm Med (2009) 0.91
Respiratory syncytial virus infections enhance cigarette smoke induced COPD in mice. PLoS One (2014) 0.90
Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis (2012) 0.90
A bibliometric analysis of the 100 most influential papers on COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.90
In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study. PLoS One (2014) 0.90
Maternal smoking promotes chronic obstructive lung disease in the offspring as adults. Eur J Med Res (2009) 0.89
Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. Biomed Res Int (2014) 0.89
The effect of cold temperature on increased exacerbation of chronic obstructive pulmonary disease: a nationwide study. PLoS One (2013) 0.89
The role of microparticles in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.89
Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respir Med (2010) 0.89
Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. NPJ Prim Care Respir Med (2015) 0.88
Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study. PLoS One (2014) 0.88
Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.88
Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2013) 0.88
Predictors of exacerbations of asthma and COPD during one year in primary care. Fam Pract (2013) 0.88
A score to predict short-term risk of COPD exacerbations (SCOPEX). Int J Chron Obstruct Pulmon Dis (2015) 0.88
Optimising treatment for COPD--new strategies for combination therapy. Int J Clin Pract (2009) 0.87
Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung (2011) 0.87
Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.87
Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. Respir Res (2011) 0.87
A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int J Chron Obstruct Pulmon Dis (2011) 0.87
Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. PLoS One (2014) 0.87
Detecting exacerbations using the Clinical COPD Questionnaire. Health Qual Life Outcomes (2010) 0.87
Asthma, airflow limitation and mortality risk in the general population. Eur Respir J (2014) 0.87
Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort. PLoS One (2014) 0.86
Six-minute-walk distance and accelerometry predict outcomes in chronic obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group. Ann Am Thorac Soc (2015) 0.86
Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease. Respir Res (2012) 0.86
Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend. Am Health Drug Benefits (2014) 0.86
Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis (2009) 0.86
Prevalence and risk factors for reflux esophagitis in patients with chronic obstructive pulmonary disease. Korean J Intern Med (2014) 0.86
IL-22 Defect During Streptococcus pneumoniae Infection Triggers Exacerbation of Chronic Obstructive Pulmonary Disease. EBioMedicine (2015) 0.86
Targeting IL-1β and IL-17A driven inflammation during influenza-induced exacerbations of chronic lung inflammation. PLoS One (2014) 0.85
Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis (2013) 0.85
Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links. Biomed Res Int (2014) 0.85
Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation. BMC Pulm Med (2012) 0.85
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2010) 0.85
Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax (2015) 0.85
Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis (2009) 0.84
Comparison of clinico-physiologic and CT imaging risk factors for COPD exacerbation. J Korean Med Sci (2011) 0.84
Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol (2014) 0.84
BODE-Index vs HADO-score in chronic obstructive pulmonary disease: Which one to use in general practice? BMC Med (2010) 0.84
Admission prevention in COPD: non-pharmacological management. BMC Med (2013) 0.83
Results from an audit feedback strategy for chronic obstructive pulmonary disease in-hospital care: a joint analysis from the AUDIPOC and European COPD audit studies. PLoS One (2014) 0.83
Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLoS One (2011) 0.83
Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Inflammation (2015) 0.83
Two-year mortality of patients with COPD in primary health care: an observational study. Int J Gen Med (2012) 0.83
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 29.18
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med (2004) 18.60
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 10.05
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax (2002) 8.77
Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med (1996) 5.82
Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 4.74
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax (2003) 4.53
Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med (2001) 4.48
Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax (2002) 4.26
Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest (2002) 3.82
Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA (1995) 3.45
Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med (2000) 3.43
Mortality after hospitalization for COPD. Chest (2002) 3.37
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J (2002) 3.22
Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis (1986) 3.03
Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest (2003) 2.90
Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 2.63
Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir (1986) 2.52
Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med (2002) 2.41
Pharmacoeconomic evaluation of COPD. Chest (2000) 2.35
Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest (1995) 2.22
The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J (2004) 2.14
Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J (1997) 2.04
Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 1.85
Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J (2003) 1.78
Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. Respir Med (1999) 1.56
The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest (2000) 1.49
Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med (1995) 1.42
Prediction of survival in patients with chronic airway obstruction. Am Rev Respir Dis (1969) 1.30
[The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization]. Arch Bronconeumol (2001) 1.01
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med (2001) 5.95
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci (1999) 3.45
An anorexic lipid mediator regulated by feeding. Nature (2001) 2.94
A conserved RNA structure (thi box) is involved in regulation of thiamin biosynthetic gene expression in bacteria. Proc Natl Acad Sci U S A (2001) 2.88
Renal injury in the extremely obese patients with normal renal function. Kidney Int (2008) 2.83
Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med (1998) 2.68
Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science (1997) 2.50
Should the angiotensin II antagonists be discontinued before surgery? Anesth Analg (2001) 2.41
[Ischemic stroke and sleep apnea. Relationship between sleep breathing disorders and carotid stenosis]. Neurologia (2005) 2.00
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol (2009) 1.81
Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst (2000) 1.80
High-resolution PLA-based composite scaffolds via 3-D printing technology. Acta Biomater (2012) 1.67
Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. Euro Surveill (2011) 1.54
International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother (1983) 1.52
alpha-Interferon therapy for congenital dyserythropoiesis type I. Br J Haematol (1995) 1.46
[Morbidity from patients admitted for heart failure in the departments of internal medicine]. Rev Clin Esp (2010) 1.41
Reengineering respiratory support following extubation: avoidance of critical care unit costs. Chest (1999) 1.39
Technical improvements in corrosion casting of small specimens: a study on mesonephric tubules and vessels of chicken embryos. Scanning Microsc (1993) 1.39
Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res (1999) 1.33
Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci (2000) 1.31
Chagas disease in Latin American migrants: a Spanish challenge. Clin Microbiol Infect (2010) 1.27
Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer (2004) 1.27
Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: a case series. Endoscopy (2007) 1.27
Histopathologic and immunohistochemical diagnosis of benign and malignant fibrous and fibrohistiocytic tumors of the skin. Dermatol Clin (1999) 1.20
PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene (1999) 1.19
The molecular karyotype of the megabase chromosomes of Trypanosoma brucei stock 427. Mol Biochem Parasitol (2000) 1.16
Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis (1991) 1.12
Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism (2000) 1.11
Regulation of vsg expression site transcription and switching in Trypanosoma brucei. Mol Biochem Parasitol (1998) 1.11
Amaurosis fugax in a patient with a left ventricular endocardial pacemaker. Pacing Clin Electrophysiol (1984) 1.11
Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma protuberans (DP). Oncogene (2001) 1.10
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer (2010) 1.10
Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes. J Med Chem (1996) 1.09
Leukemia-associated changes identified by quantitative flow cytometry. II. CD5 over-expression and monitoring in B-CLL. Leukemia (1994) 1.09
Insulin receptor substrate-1, p70S6K, and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem (2000) 1.08
Inverse paradoxical embolism in a patient on chronic hemodialysis with aortic bacterial endocarditis. Am J Kidney Dis (1999) 1.07
Characterization of three genes encoding enzymes of the folate biosynthetic pathway in Plasmodium falciparum. Parasitology (2001) 1.06
Refinement of the Medicare diagnosis-related groups to incorporate a measure of severity. Health Care Financ Rev (1994) 1.05
New tubulins in protozoal parasites. Curr Biol (2000) 1.05
Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther (1996) 1.04
Posterior urethral valves: prognostic factors. BJU Int (2003) 1.04
Honeybee blue- and ultraviolet-sensitive opsins: cloning, heterologous expression in Drosophila, and physiological characterization. J Neurosci (1998) 1.04
Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience (2003) 1.03
Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant (2007) 1.03
Risk assessment in skin gene therapy: viral-cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors. Gene Ther (2011) 1.02
First record of the rare species Aeromonas culicicola from a drinking water supply. Appl Environ Microbiol (2005) 1.02
Antibacterial and free-radical scavenging activities of Sonoran propolis. J Appl Microbiol (2007) 1.00
Adverse reactions to injectable aesthetic microimplants. Am J Dermatopathol (2001) 0.99
Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol (1999) 0.99
The value of fat-suppressed T2 or STIR sequences in distinguishing lipoma from well-differentiated liposarcoma. Eur Radiol (2002) 0.99
Single-tube balanced heminested PCR for detecting Mycobacterium tuberculosis in smear-negative samples. J Clin Microbiol (2000) 0.97
A study of 15 cases of primary mediastinal lymphoma of B-cell type. Cancer (1992) 0.97
[Drug-induced extrapyramidal disorders]. Rev Neurol (1996) 0.97
Use of microscopic morphology in smears prepared from radiometric cultures for presumptive identification of Mycobacterium tuberculosis complex, Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi. Eur J Clin Microbiol Infect Dis (1998) 0.96
The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clin Transl Oncol (2007) 0.95
Aminoglycoside-phosphotransferases APH(3')-IV and APH(3") synthesized by a strain of Campylobacter coli. J Antimicrob Chemother (1986) 0.95
Deafness and blindness in a HIV-positive patient with cryptococcal meningitis. Postgrad Med J (1996) 0.95
Response to neoadjuvant therapy for rectal cancer: influence on long-term results. Colorectal Dis (2005) 0.94
Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis (1998) 0.94
Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation (2001) 0.94
Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias. Leukemia (1994) 0.94
Increased glucagon-like peptide-1 receptor expression in glia after mechanical lesion of the rat brain. Neuropeptides (1999) 0.93
An international outbreak of Vero cytotoxin-producing Escherichia coli O157 infection amongst tourists; a challenge for the European infectious disease surveillance network. Epidemiol Infect (1999) 0.92
Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao (1999) 0.92
Insulin-like growth factor I receptor signaling in differentiation of neuronal H19-7 cells. Cancer Res (2000) 0.92
Regulation of the differentiation-related gene Drg-1 during mouse skin carcinogenesis. Mol Carcinog (2001) 0.92
Pelvic insufficiency fractures in patients with pelvic irradiation. Int J Radiat Oncol Biol Phys (1999) 0.92
Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. Breast-Expressive Supportive Therapy study. Cancer Treat Rev (1996) 0.91
Effects of B1 and B2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol (1996) 0.91
Mercury in pilot whales: possible limits to the detoxification process. Sci Total Environ (1996) 0.90
Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost (2004) 0.90
Chromosomal origin of acetyltransferase AAC(6') specifying amikacin resistance in Serratia marcescens. Microbiologia (1987) 0.90
[Placement of a double-lumen tube using a 6 mm diameter fibro-bronchoscope and a Cook exchange catheter in a patient with unforeseen tracheal intubation difficulty]. Rev Esp Anestesiol Reanim (2002) 0.90
Towards guidelines for dialysis in children with end-stage renal disease. Pediatr Nephrol (2000) 0.89
[Epidemiology of chronic kidney disease in Spanish pediatric population. REPIR II Project]. Nefrologia (2010) 0.87
Dilated cardiomyopathy and mitochondrial dysfunction in Sirt1-deficient mice: a role for Sirt1-Mef2 in adult heart. J Mol Cell Cardiol (2012) 0.87
High risk of bacterobilia in advanced experimental chronic fasciolosis. Acta Trop (2006) 0.87
P300 component of the auditory event-related potentials and dyslexia. Funct Neurol (1991) 0.86
Does treatment of bladder dysfunction prior to renal transplant improve outcome in patients with posterior urethral valves? Pediatr Transplant (2000) 0.86
Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol (1995) 0.86
The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity (1991) 0.86
Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox Res (2001) 0.86
Determination of total arsenic levels by hydride generation atomic absorption spectrometry in foods from south-east Spain: estimation of daily dietary intake. Food Addit Contam (2003) 0.86
Systemic lupus erythematosus in men: clinical and immunological characteristics. Ann Rheum Dis (1992) 0.86
Serum selenium in institutionalized elderly subjects and relation to other nutritional markers. Clin Chem (1997) 0.85
Regulation of Id2 gene expression by the insulin-like growth factor I receptor requires signaling by phosphatidylinositol 3-kinase. J Biol Chem (2001) 0.85
Antihepatotoxic activity of Rosmarinus tomentosus in a model of acute hepatic damage induced by thioacetamide. Phytother Res (2000) 0.85
Seroprevalence and epidemiology of Helicobacter pylori infection in patients with cirrhosis. J Hepatol (1997) 0.85
Protocol core needle biopsy and histological chronic allograft damage index as surrogate endpoint for Long-Term graft survival. Transplant Proc (2004) 0.85
[Hepatic granulocytic sarcoma: an unusual presentation]. An Med Interna (2003) 0.85
Targeted disruption of expression site-associated gene-1 in bloodstream-form Trypanosoma brucei. Mol Biochem Parasitol (1996) 0.85
[Deaf-mutism, lymphedema of the lower limbs and hematological abnormalities (acute leukemia, cytopenia) with autosomal dominant transmission]. J Genet Hum (1979) 0.85
The role of the insulin receptor substrate-1 in the differentiation of rat hippocampal neuronal cells. Oncogene (2001) 0.85
Renal ischemia-induced increase in vascular permeability is limited by hypothermia. Immunopharmacology (1999) 0.84
CYLD regulates keratinocyte differentiation and skin cancer progression in humans. Cell Death Dis (2011) 0.84